171 related articles for article (PubMed ID: 36083313)
1. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.
Español-Rego M; Fernández-Martos C; Elez E; Foguet C; Pedrosa L; Rodríguez N; Ruiz-Casado A; Pineda E; Cid J; Cabezón R; Oliveres H; Lozano M; Ginés A; García-Criado A; Ayuso JR; Pagés M; Cuatrecasas M; Torres F; Thomson T; Cascante M; Benítez-Ribas D; Maurel J
Cancer Immunol Immunother; 2023 Apr; 72(4):827-840. PubMed ID: 36083313
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
[TBL] [Abstract][Full Text] [Related]
3. Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.
Fang X; Zhong C; Weng S; Hu H; Wang J; Xiao Q; Wang J; Sun L; Xu D; Liao X; Dong C; Zhang S; Li J; Ding K; Yuan Y
BMC Cancer; 2023 Jul; 23(1):676. PubMed ID: 37464378
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.
Martini G; Ciardiello D; Dallio M; Famiglietti V; Esposito L; Corte CMD; Napolitano S; Fasano M; Gravina AG; Romano M; Loguercio C; Federico A; Maiello E; Tuccillo C; Morgillo F; Troiani T; Di Maio M; Martinelli E; Ciardiello F
Int J Cancer; 2022 Aug; 151(3):473-480. PubMed ID: 35429341
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
[TBL] [Abstract][Full Text] [Related]
6. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients.
Caballero-Baños M; Benitez-Ribas D; Tabera J; Varea S; Vilana R; Bianchi L; Ayuso JR; Pagés M; Carrera G; Cuatrecasas M; Martin-Richard M; Cid J; Lozano M; Castells A; García-Albéniz X; Maurel J; Vilella R
Eur J Cancer; 2016 Sep; 64():167-74. PubMed ID: 27428073
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
Kim JH; Kim SY; Baek JY; Cha YJ; Ahn JB; Kim HS; Lee KW; Kim JW; Kim TY; Chang WJ; Park JO; Kim J; Kim JE; Hong YS; Kim YH; Kim TW
Cancer Res Treat; 2020 Oct; 52(4):1135-1144. PubMed ID: 32340084
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
[TBL] [Abstract][Full Text] [Related]
9. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
[TBL] [Abstract][Full Text] [Related]
10. Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience.
Jin Z; Sanhueza CT; Johnson B; Nagorney DM; Larson DW; Mara KC; Harmsen WC; Smyrk TC; Grothey A; Hubbard JM
Oncologist; 2018 Sep; 23(9):1083-1091. PubMed ID: 29674439
[TBL] [Abstract][Full Text] [Related]
11. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
13. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
[TBL] [Abstract][Full Text] [Related]
14. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
[TBL] [Abstract][Full Text] [Related]
15. Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study.
Hubbard JM; Tőke ER; Moretto R; Graham RP; Youssoufian H; Lőrincz O; Molnár L; Csiszovszki Z; Mitchell JL; Wessling J; Tóth J; Cremolini C
Clin Cancer Res; 2022 Jul; 28(13):2818-2829. PubMed ID: 35472243
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer.
Redman JM; Tsai YT; Weinberg BA; Donahue RN; Gandhy S; Gatti-Mays ME; Abdul Sater H; Bilusic M; Cordes LM; Steinberg SM; Marte JL; Jochems C; Kim SS; Marshall JL; McMahon S; Redmond E; Schlom J; Gulley JL; Strauss J
Oncologist; 2022 Mar; 27(3):198-209. PubMed ID: 35274710
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Metastatic Colorectal Cancer: ASCO Guideline.
Morris VK; Kennedy EB; Baxter NN; Benson AB; Cercek A; Cho M; Ciombor KK; Cremolini C; Davis A; Deming DA; Fakih MG; Gholami S; Hong TS; Jaiyesimi I; Klute K; Lieu C; Sanoff H; Strickler JH; White S; Willis JA; Eng C
J Clin Oncol; 2023 Jan; 41(3):678-700. PubMed ID: 36252154
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.
Gallois C; Emile JF; Kim S; Monterymard C; Gilabert M; Bez J; Lièvre A; Dahan L; Laurent-Puig P; Mineur L; Coriat R; Legoux JL; Hautefeuille V; Phelip JM; Lecomte T; Sokol H; Capron C; Randrian V; Lepage C; Lomenie N; Kurtz C; Taieb J; Tougeron D
Dig Liver Dis; 2021 Oct; 53(10):1254-1259. PubMed ID: 34215534
[TBL] [Abstract][Full Text] [Related]
19. Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.
Ducreux M; Tabernero J; Grothey A; Arnold D; O'Dwyer PJ; Gilberg F; Abbas A; Thakur MD; Prizant H; Irahara N; Tahiri A; Schmoll HJ; Van Cutsem E; de Gramont A
Eur J Cancer; 2023 May; 184():137-150. PubMed ID: 36921494
[TBL] [Abstract][Full Text] [Related]
20. Predictive Impact of
Moretto R; Germani MM; Ros J; Daniel F; Ghelardi F; Vetere G; Giordano M; Toledo RA; Bergamo F; Randon G; Elez E; Lonardi S; Pietrantonio F; Vignali P; Rossini D; Matito J; Ugolini C; Fontanini G; Masi G; Cremolini C
JCO Precis Oncol; 2023 Sep; 7():e2300255. PubMed ID: 37797285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
